128 related articles for article (PubMed ID: 2539689)
1. Cytomegalovirus infection and disease after T cell depleted allogeneic bone marrow transplantation for malignant hematologic diseases.
Engelhard D; Or R; Strauss N; Morag A; Aker M; Naparstek E; Breuer R; Ravid Z; Sarov I; Lijovetzky G
Transplant Proc; 1989 Feb; 21(1 Pt 3):3101-2. PubMed ID: 2539689
[No Abstract] [Full Text] [Related]
2. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT.
Hertenstein B; Hampl W; Bunjes D; Wiesneth M; Duncker C; Koszinowski U; Heimpel H; Arnold R; Mertens T
Bone Marrow Transplant; 1995 Mar; 15(3):387-93. PubMed ID: 7599563
[TBL] [Abstract][Full Text] [Related]
3. Interstitial pneumonitis in T cell-depleted bone marrow transplantation.
Breuer R; Or R; Lijovetzky G; Naparstek E; Engelhard D; Lafair J; Weshler Z; Slavin S
Bone Marrow Transplant; 1988 Nov; 3(6):625-30. PubMed ID: 2850831
[TBL] [Abstract][Full Text] [Related]
4. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
Walker CM; van Burik JA; De For TE; Weisdorf DJ
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
[TBL] [Abstract][Full Text] [Related]
6. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
Habib K; Lamia T; Amel L; Abdelrahmen A; Saloua L; Hana E; Amine S; Bechir Z; Tarek BO; Assia BH
Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin.
Krischer J; Elfenbein G; Babington R; Hong R; Jansen J; Lazarus H; Winton E; Rand K
Semin Hematol; 1992 Jul; 29(3 Suppl 2):89-95. PubMed ID: 1324530
[No Abstract] [Full Text] [Related]
8. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
9. The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders.
Slavin S; Naparstek E; Aker M; Cividalli G; Engelhard D; Hardan Y; Bromiker R; Brautbar C; Weshler Z; Or R
Transplant Proc; 1989 Feb; 21(1 Pt 3):3053-4. PubMed ID: 2650422
[No Abstract] [Full Text] [Related]
10. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
11. Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
Trigg ME; Sondel PM; Billing R; Finlay JL; Peterson A; Hong R; Frierdich S; Shahidi N
J Biol Response Mod; 1985 Dec; 4(6):602-12. PubMed ID: 3910764
[TBL] [Abstract][Full Text] [Related]
12. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
Marciniak E; Romond EH; Thompson JS; Henslee PJ
Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
[TBL] [Abstract][Full Text] [Related]
13. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
14. Interim results of a multicenter trial to prevent cytomegalovirus pneumonia after allogeneic bone marrow transplantation.
Elfenbein G; Krischer J; Babington R; Hong R; Jansen J; Lazarus H; Winton E; Rand K
Transplant Proc; 1989 Feb; 21(1 Pt 3):3099-100. PubMed ID: 2539688
[No Abstract] [Full Text] [Related]
15. Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy.
Wang JY; Chang YL; Lee LN; Chen JH; Tang JL; Yang PC; Lee YC
Ann Thorac Surg; 2004 Jul; 78(1):267-72. PubMed ID: 15223441
[TBL] [Abstract][Full Text] [Related]
16. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
17. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.
Chen C; Busson M; Rocha V; Appert ML; Lepage V; Dulphy N; Haas P; Socié G; Toubert A; Charron D; Loiseau P
Bone Marrow Transplant; 2006 Sep; 38(6):437-44. PubMed ID: 16892071
[TBL] [Abstract][Full Text] [Related]
18. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
19. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
20. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
